Effects of ZD1839 (Iressa, gefitinib) treatment on symptoms and quality of life in patients with advanced non-small cell lung cancer

Seminars in Oncology

Volumn 31, Issue SUPPL. 9, 2004, Pages 23-30

  Natale, Ronald B ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PLATINUM; PROTEIN TYROSINE KINASE INHIBITOR;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EVALUATION; FATIGUE; HUMAN; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; REVIEW; THORAX PAIN;

EID: 3042709451     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.04.010     Document Type: Article

References (25)

1. Earle C.C., Evans W.K. Management issues for stage IV non-small-cell lung cancer. Cancer Control. 4:1997;307-316
2. Bottomley A. The cancer patient and quality of life. Oncologist. 7:2002;120-125
3. Cella D.F., Bonomi A.E., Lloyd S.R., et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer. 12:1995;199-220
4. Cella D., Eton D.T., Fairclough D.L., et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol. 55:2002;285-295
5. Arteaga C.L. The epidermal growth factor receptor From mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol. 19:(suppl):2001;32s-40s
6. Raymond E., Faivre S., Armand J.P. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs. 60:(suppl 1):2000;15-23
7. Salomon D.S., Brandt R., Ciardiello F., et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 19:1995;183-232
8. Kelloff G.J., Fay J.R., Steele V.E., et al. Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev. 5:1996;657-666
9. Kurie J.M., Shin H.J.C., Lee J.S., et al. Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin Cancer Res. 2:1996;1787-1793
10. Ranson M., Hammond L.A., Ferry D., et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors results of a phase I trial. J Clin Oncol. 20:2002;2240-2250
11. Herbst R.S., Maddox A.-M., Rothenberg M.L., et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors Results of a phase I trial. J Clin Oncol. 20:2002;3815-3825
12. Baselga J., Rischin D., Ranson M., et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol. 20:2002;4292-4302
13. Kris M., Ranson M., Ferry D., et al. Phase I study of oral ZD1839 (Iressa), a novel inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TK) Evidence of good tolerability and activity. Clin Cancer Res. 5:(suppl):1999;3749s-3750s
14. Kris M.G., Herbst R., Rischin D., et al. Objective regressions in non-small cell lung cancer patients treated in phase I trials of oral ZD1839 (Iressa), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR). Lung Cancer. 29:(suppl 1):2000;72. (abstr 233)
15. Baselga J., Herbst R., LoRusso P., et al. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types evidence of activity and good tolerability. Proc Am Soc Clin Oncol. 19:2000;177a. (abstr 686)
16. Negoro S., Nakagawa K., Fukuoka M., et al. Final results of a phase I intermittent dose-escalation trial of ZD1839 ("Iressa") in Japanese patients with various solid tumours. Proc Am Soc Clin Oncol. 20:2001;324a. (abstr 1292)
17. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 21:2003;2237-2246
18. Kris M.G., Natale R.B., Herbst R.S., et al. A phase II trial of ZD1839 ("Iressa") in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol. 21:2002;292a. (abstr 1166)
19. Natale R.B., Skarin A.T., Maddox A.-M., et al. Improvement in symptoms and quality of life for advanced non-small-cell lung cancer patients receiving ZD1839 ('Iressa') in IDEAL 2. Proc Am Soc Clin Oncol. 21:2002;292a. (abstr 1167)
20. Douillard J.-Y., Giaccone G., Horai T., et al. Improvement in disease-related symptoms and quality of life in patients with advanced non-small-cell lung cancer (NSCLC) treated with ZD1839 ("Iressa") (IDEAL 1). Proc Am Soc Clin Oncol. 21:2002;299a. (abstr 1195)
21. Douillard J.-Y., Giaccone G., Horai T., et al. Improvement in disease-related symptoms and quality of life in patients with advanced non-small-cell lung cancer (NSCLC) treated with ZD1839 ("Iressa") (IDEAL 1). 2002;. Presented at the Annual Meeting of the America Society of Clinical Oncology, May 18-21, Orlando, FL
22. Douillard J.-Y., Skarin A., Baselga J., et al. Improvement in disease-related symptoms and quality of life (QOL) for advanced non-small-cell lung cancer (NSCLC) patients treated with ZD1839 in IDEAL 1 and IDEAL 2. Ann Oncol. 13:(suppl 5):2002;131. (abstr 480PD)
23. Fukuoka M., Yano S., Giaccone G., et al. Final results from a phase II trial of ZD1839 ("Iressa") for patients with advanced non-small-cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol. 21:2002;298a. (abstr 1188)
24. Natale R., Skarin A., Maddox A., et al. Improvement in symptoms and quality of life for advanced non-small-cell lung cancer patients receiving ZD1839 ("Iressa") in IDEAL 2. 2002;. Presented at the Annual Meeting of the American Society of Clinical Oncology, May 18-21, Orlando, FL
25. Cella D., Natale R.B., Lynch T.J., et al. Disease-related symptoms in advanced non-small-cell lung cancer as measured by the lung cancer subscale of the FACT-L questionnaire Clinically meaningful improvement with gefitinib ("Iressa", ZD1839). 2003;. Presented at the American Society of Clinical Oncology, May 31-June 3, Chicago, IL